High Intensity Interval Training in Youth With Congenital Heart Disease: A Prospective Clinical Trial of a Novel Telemedicine Video Game-Linked Exercise Platform

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Congenital heart disease (CHD), the most common birth defect, is present in nearly 1% of the population. CHD patients are associated with intense resource utilization and premature death in adulthood. The risk of premature death is linked with reduced exercise capacity, a finding consistently noted in youth with CHD. Reduced exercise capacity in this population has also been associated with reduce physical activity and health-related quality of life. Cardiac rehabilitation (CR) in adults with acquired heart disease is an established secondary prevention strategy that improves exercise capacity. The investigators propose a prospective clinical trial of a home-based high intensity interval training (HIIT) program using a novel telemedicine-equipped video game-linked cycle ergometer (MedBIKE™) for 10 to 18 year olds with repaired moderate-complex CHD. The pilot study with the MedBIKE has shown promising results. The investigators now seek to study the efficacy of this program in a broader CHD population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 18
Healthy Volunteers: f
View:

• Children and adolescents aged 10-18 years

• Repaired moderate-complex congenital heart disease

Locations
Other Locations
Canada
University of Alberta
RECRUITING
Edmonton
Contact Information
Primary
Rae Foshaug
rae.foshaug@albertahealthservices.ca
7804077499
Backup
Michael Khoury, MD
khoury1@ualberta.ca
7804920103
Time Frame
Start Date: 2022-11-22
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 44
Treatments
Experimental: MedBIKE HIIT
MedBIKE HIIT Exercise Program
Related Therapeutic Areas
Sponsors
Collaborators: Heart and Stroke Foundation of Canada
Leads: University of Alberta

This content was sourced from clinicaltrials.gov